Bionaut Labs Closes $43M in Series B Led by Khosla Ventures to Advance First-in-Class Micro-Robotic Technology and Remove Barriers to Treat Rare and Debilitating Diseases
Retrieved on:
Monday, November 28, 2022
Research, Pharmaceutical, Robotics, Mental Health, Medical Devices, Technology, Clinical Trials, Science, Nanotechnology, Biotechnology, FDA, Health, PrimeSense, Compound, Magnetism, Khosla Ventures, Use, Engineering, Prevalence, Max Planck Institute for Experimental Medicine, IND, Safety, Brain, Facial recognition, Toxicity, Neuroscience, Ageing, Neurodegeneration, 3D, Pectus carinatum, Central nervous system, Deep Insight, Drug development, OurCrowd, CNS, Face ID, IDE, Hydrocephalus, Revolution, Max Planck Society, Robotics, BNL, Therapeutic index, Huntington's disease, Therapy, Venture, Traffic barrier, Biology, Glioma, FDA, Medical device, Pharmaceutical industry, Medical imaging, Labs, Apple
By reaching the midbrain safely through novel routes, Bionaut Labs aims to develop solutions to treat the most debilitating conditions including Parkinsons disease and Huntington's disease, malignant glioma and hydrocephalus.
Key Points:
- By reaching the midbrain safely through novel routes, Bionaut Labs aims to develop solutions to treat the most debilitating conditions including Parkinsons disease and Huntington's disease, malignant glioma and hydrocephalus.
- Funds will be used to advance clinical development of the companys lead programs against malignant glioma brain tumors and Dandy-Walker Syndrome (a rare pediatric neurological disorder).
- Bionaut Labs remains committed to finding new ways to treat these devastating diseases, which are long overdue for a breakthrough.
- We are extremely excited about the transformative potential Bionaut presents in treating debilitating neurological disorders, said Vinod Khosla, founder of Khosla Ventures.